Clarus Lifesciences II, L.P. [Rocket]

Date Filed	Type	Description
06/12/2019	SC 13D/A	Clarus Lifesciences II, L.P. reports a 0.3% stake in NanoString Technologies, Inc.
03/22/2019	SC 13D/A	Clarus Lifesciences II, L.P. reports a 6.1% stake in NanoString Technologies, Inc.
02/14/2019	SC 13G/A	Clarus Lifesciences II, L.P. reports a 4.2% stake in Restoration Robotics, Inc.
07/25/2018	SC 13D/A	Clarus Lifesciences II, L.P. reports a 14% stake in NanoString Technologies, Inc.
04/04/2018	SC 13D/A	Clarus Lifesciences II, L.P. reports a 7% stake in Catabasis Pharmaceuticals, Inc.
02/12/2018	SC 13G	Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/09/2018	SC 13D/A	Clarus Lifesciences II, L.P. reports a 12% stake in Catabasis Pharmaceuticals, Inc.
06/07/2017	SC 13D/A	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/13/2017	SC 13D/A	Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend]
10/04/2016	SC 13D/A	CATABASIS PHARMACEUTICALS INC reports a 15.4% stake in Catabasis Pharmaceuticals, Inc.
03/16/2016	SC 13D/A	Clarus Lifesciences II, L.P. reports a 0% stake in TetraLogic Pharmaceuticals Corporation
02/05/2016	SC 13D/A	Clarus Lifesciences II, L.P. reports a 16% stake in TetraLogic Pharmaceuticals Corporation
11/04/2013	SC 13D	Clarus Lifesciences II, L.P. reports a 16.5% stake in Aerie Pharmaceuticals, Inc.
08/25/2010	SC 13D/A	Form SC 13D - General statement of acquisition of beneficial ownership [amend]
01/08/2010	SC 13D/A	Clarus Lifesciences II, L.P. reports a 20.1% stake in Achillion Pharmaceuticals, Inc.
08/22/2008	SC 13D	Form SC 13D -- General statement of acquisition of beneficial ownership